These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39050755)

  • 1. Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis.
    Ke L; Li S; Huang D; Wang Y
    Front Pharmacol; 2024; 15():1413985. PubMed ID: 39050755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
    Yin S; Zheng X; Zhang W; Zhao H; Zhang R; Li W; Chen F
    Ann Hematol; 2024 Jul; 103(7):2231-2244. PubMed ID: 37843620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis.
    Abushukair H; Syaj S; Ababneh O; Qarqash A; Schinke C; Thanendrarajan S; Zangari M; van Rhee F; Al Hadidi S
    Am J Hematol; 2022 Jul; 97(7):942-950. PubMed ID: 35358350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Nguyen TT; Thanh Nhu N; Tran VK; Van Cau N; Lin CF
    J Immunother; 2023 Oct; 46(8):299-309. PubMed ID: 37216406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis.
    Nguyen TT; Nhu NT; Tran VK; Nguyen TTH; Lin CF
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis.
    Nguyen TT; Nhu NT; Tran VK; Viet-Nhi NK; Ho XD; Jhan MK; Chen YP; Lin CF
    Sci Rep; 2023 Jun; 13(1):9775. PubMed ID: 37328530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia.
    Liu X; Hu B; Peng N; Chen L; Hu D; Zhang J; Wang L; Xie Z; Niu S; Lu Q; Lu J; Fang Y
    Clin Exp Med; 2023 Dec; 23(8):4237-4248. PubMed ID: 37831432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of the efficacy and adverse effects of acalabrutinib in the management of relapsed/refractory chronic lymphocytic leukemia.
    Park D; Chan-Golston AM; Yan Y; Al-Manaseer F; Akhtari M
    J Chemother; 2024 May; ():1-12. PubMed ID: 38803142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative safety of novel targeted therapies in relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis.
    Monica M; Reczek M; Kawalec P
    Ther Adv Med Oncol; 2024; 16():17588359241285988. PubMed ID: 39391352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
    Wang Z; Zhou H; Xu J; Wang J; Niu T
    Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
    Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
    J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia.
    Monica M; Reczek M; Kawalec P
    Ther Adv Med Oncol; 2024; 16():17588359241263710. PubMed ID: 39091602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
    Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
    Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Invasive Fungal Infections in Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors: A Case-Control Propensity Score-Matched Analysis.
    Agudelo Higuita NI; Chastain DB; Scott B; Sahra S; Vargas Barahona L; Henao Cordero J; Lee ALH; Tuells J; Henao-Martínez AF
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae115. PubMed ID: 38887474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.
    Wu JJ; Wade SW; Itani T; Castaigne JG; Kloos I; Peng W; Kanters S; Zoratti MJ; Dreyling M; Shah B; Wang M
    Leuk Lymphoma; 2024 Nov; 65(11):1609-1622. PubMed ID: 38975903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapy for chronic lymphocytic leukaemia.
    Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
    Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia.
    Perutelli F; Montalbano MC; Boccellato E; Coscia M; Vitale C
    Curr Opin Oncol; 2022 Nov; 34(6):757-767. PubMed ID: 35993294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.
    Zhou K; Wang T; Pan L; Xu W; Jin J; Zhang W; Hu Y; Hu J; Feng R; Li P; Liu Z; Liu P; Jing H; Gao S; Zhang H; Yu K; Wang Z; Zhu X; Sun Z; Li F; Yan D; Weng J; Fu L; Wang L; Salmi T; Wu K; Qiu L
    Ann Hematol; 2024 Oct; 103(10):4183-4191. PubMed ID: 38888616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia.
    Yang S; Wei R; Shi H; Wang Y; Lai Y; Zhao X; Lu J; Schmitz N
    Front Oncol; 2024; 14():1396913. PubMed ID: 38835372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.